We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …

Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …

The efficacy and safety or rivaroxaban versus enoxaparin/vitamin K antagonist for treatment
and prevention recurrence of venous thromboembolism (VTE) was demonstrated in the …

Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …

Background Deep vein thrombosis (DVT) and pulmonary embolism are collectively known
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …

Background In phase III trials, rivaroxaban demonstrated non-inferiority over
enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction …

The approval of rivaroxaban has changed the landscape of treatment of venous
thromboembolism (VTE). Little is known about the effect of rivaroxaban compared with …

Aims To investigate the risk of all-cause mortality, recurrent venous thromboembolism (VTE),
and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban …

Background. Rivaroxaban and apixaban are the most widely used nonvitamin K oral
anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta …

Abstract Abstract 20 Harry R. Büller, MD, PhD on behalf of the EINSTEIN Investigators.
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …